300 related articles for article (PubMed ID: 29784449)
1. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Jang BS; Kim IA
Radiother Oncol; 2018 Aug; 128(2):245-253. PubMed ID: 29784449
[TBL] [Abstract][Full Text] [Related]
2. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Jang BS; Kim IA
Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
[TBL] [Abstract][Full Text] [Related]
3. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
Front Immunol; 2020; 11():580335. PubMed ID: 33224142
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
5. A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.
Jang BS; Kim IA
Cancer Res Treat; 2020 Apr; 52(2):530-542. PubMed ID: 31801317
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas.
Yan D; Zhao Q; Du Z; Li H; Geng R; Yang W; Zhang X; Cao J; Yi N; Zhou J; Tang Z
Sci Rep; 2022 Apr; 12(1):6698. PubMed ID: 35461367
[TBL] [Abstract][Full Text] [Related]
7. A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway.
Meng J; Li P; Zhang Q; Yang Z; Fu S
Oncotarget; 2014 Jul; 5(13):4683-93. PubMed ID: 24970813
[TBL] [Abstract][Full Text] [Related]
8. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
9. Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset.
Dai D; Guo Y; Shui Y; Li J; Jiang B; Wei Q
Front Mol Biosci; 2021; 8():775562. PubMed ID: 34970597
[No Abstract] [Full Text] [Related]
10. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
[TBL] [Abstract][Full Text] [Related]
11. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
12. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
Hwang K; Koh EJ; Choi EJ; Kang TH; Han JH; Choe G; Park SH; Yearley JH; Annamalai L; Blumenschein W; Sathe M; McClanahan T; Jung H; Wang KC; Kim SK; Kim CY
J Neurooncol; 2018 Sep; 139(2):281-291. PubMed ID: 29730815
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
[TBL] [Abstract][Full Text] [Related]
16. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
17. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
[TBL] [Abstract][Full Text] [Related]
18. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
19. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
20. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]